Juan R Calvo

List of Publications by Year
in descending order

106 papers	7,069 citations	57631 44 h-index	56606 83 g-index
107 all docs	107 docs citations	107 times ranked	4849 citing authors

#	Article	IF	Citations
1	Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. Journal of Pineal Research, 2005, 39, 400-408.	3.4	712
2	Significance of Melatonin in Antioxidative Defense System: Reactions and Products. NeuroSignals, 2000, 9, 137-159.	0.5	470
3	Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB Journal, 2004, 18, 537-539.	0.2	387
4	Melatonin and Its Relation to the Immune System and Inflammation. Annals of the New York Academy of Sciences, 2000, 917, 376-386.	1.8	366
5	The role of melatonin in the cells of the innate immunity: a review. Journal of Pineal Research, 2013, 55, 103-120.	3.4	342
6	Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. Journal of Cellular Biochemistry, 1997, 65, 430-442.	1.2	263
7	Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sciences, 1994, 55, PL455-PL460.	2.0	218
8	Pharmacology and Physiology of Melatonin in the Reduction of Oxidative Stress in vivo. NeuroSignals, 2000, 9, 160-171.	0.5	215
9	Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. Journal of Pineal Research, 1995, 18, 119-126.	3.4	140
10	Human Lymphocyte-Synthesized Melatonin Is Involved in the Regulation of the Interleukin-2/Interleukin-2 Receptor System. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 992-1000.	1.8	139
11	Melatonin present in beer contributes to increase the levels of melatonin and antioxidant capacity of the human serum. Clinical Nutrition, 2009, 28, 188-191.	2.3	137
12	Expression of the Mel _{1a} â€melatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB Journal, 1997, 11, 466-473.	0.2	136
13	Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. Journal of Leukocyte Biology, 1998, 63, 591-601.	1.5	131
14	Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sciences, 1999, 65, 2143-2150.	2.0	131
15	Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. Journal of Pineal Research, 2000, 29, 129-137.	3.4	131
16	Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. Journal of Pineal Research, 2003, 35, 204-211.	3.4	122
17	Interaction of melatonin with human lymphocytes: Evidence for binding sites coupled to potentiation of cyclic AMP stimulated by vasoactive intestinal peptide and activation of cyclic GMP. Journal of Pineal Research, 1992, 12, 97-104.	3.4	117
18	Expression of membrane and nuclear melatonin receptor mRNA and protein in the mouse immune system. Cellular and Molecular Life Sciences, 2003, 60, 2272-2278.	2.4	116

#	Article	IF	Citations
19	Melatonin counteracts the inhibitory effect of PGE 2 on ILâ€2 production in human lymphocytes via its mt1 membrane receptor. FASEB Journal, 2003, 17, 755-757.	0.2	116
20	mRNA expression of nuclear receptor RZR/RORalpha, melatonin membrane receptor MT1, and hydroxindole-O-methyltransferase in different populations of human immune cells. Journal of Pineal Research, 2004, 37, 48-54.	3.4	104
21	Immunobiology of vasoactive intestinal peptide (VIP). Trends in Immunology, 2000, 21, 7-11.	7.5	101
22	Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. Journal of Neuroimmunology, 1998, 92, 76-84.	1.1	100
23	Highâ€affinity binding of melatonin by human circulating T lymphocytes (CD4 ⁺). FASEB Journal, 1995, 9, 1331-1335.	0.2	94
24	Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sciences, 2004, 74, 2227-2236.	2.0	91
25	Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacological Research, 2010, 62, 282-287.	3.1	85
26	Specific binding of 2-[125I]iodomelatonin by rat splenocytes: characterization and its role on regulation of cyclic AMP production. Journal of Neuroimmunology, 1995, 57, 171-178.	1.1	77
27	VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies1The first two authors have contributed equally to the present work.1. Journal of Neuroimmunology, 1998, 85, 155-167.	1.1	72
28	Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides, 2008, 29, 2001-2012.	1.2	70
29	Characterization of the protective effects of melatonin and related indoles against ?-naphthylisothiocyanate-induced liver injury in rats. Journal of Cellular Biochemistry, 2001, 80, 461-470.	1.2	67
30	Specific binding of melatonin by purified cell nuclei from spleen and thymus of the rat. Journal of Neuroimmunology, 1998, 86, 190-197.	1.1	64
31	Interaction of vasoactive intestinal peptide (VIP) with rat lymphoid cells. Peptides, 1986, 7, 177-181.	1.2	62
32	Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages. Regulatory Peptides, 1991, 33, 133-143.	1.9	62
33	Interaction of vasoactive intestinal peptide (VIP) with human peripheral blood lymphocytes: Specific binding and cyclic AMP production. General Pharmacology, 1986, 17, 185-189.	0.7	61
34	Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages1David Pozo and Mario Delgado contributed equally to this work.1. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1359, 250-262.	1.9	58
35	In vitro effect of the resin component bisphenol A on substrate adherence capacity of macrophages. Journal of Endodontics, 1999, 25, 341-344.	1.4	57
36	Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regulatory Peptides, 1996, 62, 161-166.	1.9	52

#	Article	IF	Citations
37	Characterization of melatonin binding sites in the Harderian gland and median eminence of the rat. Life Sciences, 1991, 48, 1165-1171.	2.0	51
38	High levels of melatonin generated during the brewing process. Journal of Pineal Research, 2013, 55, 26-30.	3.4	50
39	Glycogenolytic effect of pancreastatin in the rat. Bioscience Reports, 1990, 10, 87-91.	1.1	49
40	Characterization of membrane melatonin receptor in mouse peritoneal macrophages: inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein. Journal of Neuroimmunology, 1999, 95, 85-94.	1.1	49
41	Melatonin administrated immediately before an intense exercise reverses oxidative stress, improves immunological defenses and lipid metabolism in football players. Physiology and Behavior, 2012, 105, 1099-1103.	1.0	49
42	Binding of 2-[125I]melatonin by rat thymus membranes during postnatal development. Immunology Letters, 1993, 36, 59-63.	1.1	48
43	Specific binding of 2-[125I]melatonin by partially purified membranes of rat thymus. Journal of Neuroimmunology, 1993, 45, 121-126.	1.1	47
44	Melatonin as pharmacologic support in burn patients: A proposed solution to thermal injuryâ€“related lymphocytopenia and oxidative damage. Critical Care Medicine, 2007, 35, 1177-1185.	0.4	47
45	The disodium salt of EDTA inhibits the binding of vasoactive intestinal peptide to macrophage membranes: Endodontic implications. Journal of Endodontics, 1996, 22, 337-340.	1.4	46
46	Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Advances in Neuroimmunology, 1996, 6, 39-47.	1.8	42
47	N-acetylserotonin suppresses hepatic microsomal membrane rigidity associated with lipid peroxidation. European Journal of Pharmacology, 2001, 428, 169-175.	1.7	42
48	Acutely administered melatonin is beneficial while chronic melatonin treatment aggravates the evolution of TNBS-induced colitis. Journal of Pineal Research, 2006, 40, 48-55.	3.4	40
49	Synergistic action of melatonin and vasoactive intestinal peptide in stimulating cyclic AMP production in human lymphocytes. Journal of Pineal Research, 1992, 12, 174-180.	3.4	39
50	Galanin in the trinitrobenzene sulfonic acid rat model of experimental colitis. International Immunopharmacology, 2006, 6, 1404-1412.	1.7	38
51	Involvement of Nuclear Receptors in the Enhanced ILâ€2 Production by Melatonin in Jurkat Cells. Annals of the New York Academy of Sciences, 2000, 917, 397-403.	1.8	38
52	Expression of VIP receptors in mouse peritoneal macrophages: Functional and molecular characterization. Journal of Neuroimmunology, 1994, 50, 85-93.	1.1	37
53	Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research, 2002, 32, 277-278.	3.4	37
54	EDTA inhibits in vitro substrate adherence capacity of macrophages: Endodontic implications. Journal of Endodontics, 1997, 23, 205-208.	1.4	36

#	Article	IF	Citations
55	Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regulatory Peptides, 2007, 141, 96-104.	1.9	35
56	Activation of cyclic AMP-dependent protein kinase by VIP in blood mononuclear cells. Peptides, 1984, 5, 371-373.	1.2	30
57	Possible Involvement of the Inhibition of NFâ€ÎºB Factor in Antiâ€Inflammatory Actions That Melatonin Exerts on Mast Cells. Journal of Cellular Biochemistry, 2016, 117, 1926-1933.	1.2	30
58	Stimulatory effect of vasoactive intestinal peptide (VIP) on cyclic AMP production in rat peritoneal macrophages. Regulatory Peptides, 1992, 37, 195-203.	1.9	29
59	Nuclear Receptors Are Involved in the Enhanced IL-6 Production by Melatonin in U937 Cells. NeuroSignals, 2000, 9, 197-202.	0.5	29
60	Inhibitory Effect of Melatonin on Homocysteine-Induced Lipid Peroxidation in Rat Brain Homogenates. Basic and Clinical Pharmacology and Toxicology, 2002, 90, 32-37.	0.0	29
61	Melatonin potentiates cyclic AMP production stimulated by vasoactive intestinal peptide in human lymphocytes. Neuroscience Letters, 1992, 136, 150-152.	1.0	27
62	Characteristics of receptors for VIP in rat peritoneal macrophage membranes. Peptides, 1994, 15, 309-315.	1.2	26
63	Specific binding of 2-[125I]iodomelatonin by rat spleen crude membranes: Day-night variations and effect of pinealectomy and continuous light exposure. Journal of Pineal Research, 1996, 20, 33-38.	3.4	26
64	VASOACTIVE INTESTINAL PEPTIDE AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE INHIBIT LPS-STIMULATED MIP-1Î± PRODUCTION AND mRNA EXPRESSION. Cytokine, 2002, 18, 35-42.	1.4	21
65	Pancreastatin and its 33â€"49 C-terminal fragment inhibit glucagon-stimulated insulin in vivo. General Pharmacology, 1992, 23, 637-638.	0.7	19
66	Vasoactive Intestinal Peptide (VIP) Inhibits Substrate Adherence Capacity of Rat Peritoneal Macrophages by a Mechanism That Involves cAMP. Cell Adhesion and Communication, 1993, 1, 213-221.	1.7	19
67	Expression of vasoactive intestinal peptide binding sites in rat peritoneal macrophages is stimulated by inflammatory stimulus. Journal of Neuroimmunology, 1996, 64, 1-7.	1.1	19
68	Melatonin prevents delta-aminolevulinic acid-induced oxidative DNA damage in the presence of Fe2+. Molecular and Cellular Biochemistry, 2001, 218, 87-92.	1.4	19
69	Comparative effects of two endodontic irrigants, chlorhexidine digluconate and sodium hypochlorite, on macrophage adhesion to plastic surfaces. Journal of Endodontics, 1999, 25, 243-246.	1.4	18
70	Melatonin usage in ulcerative colitis: a case report. Journal of Pineal Research, 2008, 45, 339-340.	3.4	18
71	Intestinal Immunomodulation. Role of Regulative Peptides and Promising Pharmacological Activities. Current Pharmaceutical Design, 2008, 14, 71-95.	0.9	17
72	Homologous regulation of vasoactive intestinal peptide (VIP) receptors on rat peritoneal macrophages. Peptides, 1995, 16, 313-318.	1.2	16

#	Article	IF	Citations
73	Guanine nucleotide regulation of VIP binding to rat peritoneal macrophage membranes. Peptides, 1992, 13, 953-955.	1.2	15
74	In Vitro Inhibitory Effect of EGTA on Macrophage Adhesion: Endodontic Implications. Journal of Endodontics, 2003, 29, 211-213.	1.4	15
75	The interaction of vasoactive intestinal peptide (VIP) with isolated bovine thyroid plasma membranes. Biochemical and Biophysical Research Communications, 1985, 128, 1336-1341.	1.0	13
76	Solubilization of active and stable receptors for vasoactive intestinal peptide from rat liver. Regulatory Peptides, 1989, 25, 37-50.	1.9	13
77	Somatostatin inhibition of VIP- and isoproterenol-stimulated cyclic AMP production in rat peritoneal macrophages. Neuropeptides, 1992, 23, 39-43.	0.9	12
78	Melatonin Binding Sites in the Harderian Gland of the Rat and Syrian Hamster. NeuroSignals, 1994, 3, 99-106.	0.5	12
79	Characterization of adenylyl cyclase stimulated by VIP in rat and mouse peritoneal macrophage membranes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1312, 249-254.	1.9	11
80	Specific Binding of Melatonin by Immunocompetent Cells in Humans and Rodents.. Annals of the New York Academy of Sciences, 1994, 719, 369-377.	1.8	10
81	Melatonin protects mast cells against cytotoxicity mediated by chemical stimuli PMACI: Possible clinical use. Journal of Neuroimmunology, 2013, 262, 62-65.	1.1	9
82	Interaction of thymic peptide thymosin Î±1 with VIP receptors in rat intestinal epithelial cells: Comparison with PHI and secretin. General Pharmacology, 1989, 20, 503-505.	0.7	8
83	Chronic ethanol intake inhibits both the vasoactive intestinal peptide binding and the associated cyclic AMP production in rat enterocytes. General Pharmacology, 1992, 23, 607-611.	0.7	7
84	Diurnal Variations in [125I]Melatonin Binding by Rat Thymus Membranes: Effects of Continuous Light Exposure and Pinealectomy. Chronobiology International, 1995, 12, 382-388.	0.9	7
85	Nucleotide regulation of vasoactive intestinal peptide binding to bovine thyroid plasma membranes. Bioscience Reports, 1990, 10, 519-525.	1.1	6
86	Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages. European Journal of Pharmacology, 1997, 321, 379-386.	1.7	6
87	Identification of G-Protein Coupled Receptor Subunits in Normal Human Dental Pulp. Journal of Endodontics, 2000, 26, 16-19.	1.4	6
88	The perception that beer improves sleep onset might be a motivation for some to drink heavily. Is it only melatonin that matters? Reply to Dr. Molfino. Clinical Nutrition, 2010, 29, 273-274.	2.3	5
89	The role of melatonin in autoimmune and atopic diseases. AIMS Molecular Science, 2016, 3, 158-186.	0.3	5
90	Effect of chronic intake of ethanol on the binding of vasoactive intestinal peptide to rat spleen lymphoid cells. General Pharmacology, 1989, 20, 659-662.	0.7	4

#	Article	IF	Citations
91	Functional and molecular characterization of VIP receptorâ€“effector system in rat developing immunocompetent cells: G protein involvement. Journal of Neuroimmunology, 2000, 103, 41-50.	1.1	4
92	VIP receptorâ€"Effector system in rat Harderian gland and its coupling to activation of type II thyroxine 5â€²-deiodinase. Peptides, 1995, 16, 551-557.	1.2	3
93	Mechanisms of Action of Melatonin on the Human Immune System. Membrane versus Nuclear Receptors. , 1997, 23, 43-51.		3
94	Vasoactive intestinal peptide (VIP) binding to solubilized material from rat liver plasma membranes. Bioscience Reports, 1986, 6, 39-44.	1.1	2
95	Decreased binding of vasoactive intestinal peptide to intestinal epithelial cells from hypothyroid rats. Biochemical and Biophysical Research Communications, 1989, 162, 701-707.	1.0	2
96	Characterization of binding sites for Î²-adrenergic agonists and vasoactive intestinal peptide in the rat Harderian gland. , 1996, 34, 139-143.		2
97	Expression of Membrane Melatonin Receptor mRNA in Rat Thymus and Spleen. , 1997, 23, 36-42.		2
98	Mechanisms Involved in the Immunomodulatory Effects of Melatonin on the Human Immune System. , 2001, , 408-416.		2
99	Interaction of a bovine thymic peptide extract with vasoactive intestinal peptide (VIP) receptors. Bioscience Reports, 1986, 6, 579-584.	1.1	1
100	Thymosin Î± 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells. Immunopharmacology, 1996, 34, 113-123.	2.0	1
101	Receptors for vasoactive intestinal peptide (VIP) in lymphoid cells of rat. Regulatory Peptides, 1983, 6, 306.	1.9	0
102	Effects of fasting and refeeding on vasoactive intestinal peptide binding to rat blood mononuclear cells. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1987, 87, 95-98.	0.2	0
103	Peptide T from human immunodeficiency virus does not interact with VIP receptor-effector system in immunocompetent cells of rat and mouse. Bioscience Reports, 1994, 14, 251-257.	1.1	0
104	Binding of [125I]iodocyanopindolol by rat Harderian gland crude membranes: Kinetic characteristics and dayâ€"night variations. Bioscience Reports, 1996, 16, 369-377.	1.1	0
105	Postnatal Development of Vasoactive Intestinal Peptide Receptorâ€Effector System in Rat Immunocompetent Cells. Annals of the New York Academy of Sciences, 2000, 921, 357-361.	1.8	0
106	Differential adrenergic regulation of rat pineal cyclic AMP production and N-acetyltransferase activity during postnatal development: involvement of G alpha s and G alpha i1-2 proteins. Journal of Endocrinology, 1997, 155, 305-312.	1.2	0